Setmelanotide for the Treatment of Acquired Hypothalamic Obesity.

Summary

In a 52-week randomized, placebo-controlled phase 3 trial (n=120), setmelanotide produced a −16.5% mean BMI reduction versus +3.3% with placebo and reduced maximal daily hunger. Adverse events were common (100% any; 28% serious) with typical melanocortin-related effects.

Key Findings

• Least-squares mean BMI change at 52 weeks: −16.5% (setmelanotide) vs +3.3% (placebo), P<0.001
• Maximal daily hunger score decreased more with setmelanotide (−2.73) than placebo (−1.45), P=0.009
• Adverse events occurred in 100% vs 90%; serious adverse events in 28% vs 8% (setmelanotide vs placebo); common AEs included skin hyperpigmentation, nausea, vomiting, headache

Clinical Implications

Setmelanotide may become a disease-specific pharmacotherapy for acquired hypothalamic obesity. Clinicians should monitor for melanocortin-related adverse effects and weigh benefits against the high rate of adverse events.

Limitations

• High frequency of adverse events and higher serious adverse events in the active arm
• Industry-funded trial; long-term durability and safety beyond 52 weeks and generalizability require further study

Future Directions

Evaluate long-term safety, durability, and quality-of-life impact; define optimal dosing and risk mitigation strategies; and compare with multimodal behavioral and surgical approaches.